June 28, 2010 - Program Targets 11beta-HSD-1 for the Treatment of Diabetes and Other Metabolic Syndrome Disorders - Vitae Pharmaceuticals, Inc., an integrated discovery and development company, announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies. Vitae’s 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim’s recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
“Inhibition of 11beta-HSD-1 represents an important new mechanism of action for treating diabetic patients,”... [PDF] Vitae Pharmaceuticals' Press Release -
